Pricing, Distribution, and Reimbursement
APONVIE Is Priced to Support Broad Access, With Convenient Packaging and Distribution
WAC: $62.46 per vial
Vial contains single 32-mg dose. Packaged in cartons of 10 vials.
- Discounts available under contracts with leading GPOs
- 340B, sub-WAC, and FSS pricing available
- Distribution through authorized wholesalers and specialty distributors; prime vendor discounts apply
Download the APONVIE Ordering and Pricing Information and the APONVIE Distribution Guide for more details.
Note: Pricing as of January 1, 2026. Confirm current pricing with your Heron representative.
WAC: wholesale acquisition cost.
GPO: group purchasing organization.
FSS: Federal Supply Schedule.
Medicare Reimbursement
- Physician Office: APONVIE is separately reimbursed under the Medicare Physician Fee Schedule at ASP + 6%
- HOPD/ASC/Inpatient procedures: APONVIE is packaged in the payment for the procedure in which APONVIE is used
- Critical Access Hospitals: APONVIE is reimbursed based on reasonable cost
Commercial Reimbursement
- Some commercial payers reimburse separately for APONVIE as a percentage of billed charges; however, most package APONVIE across all sites of care
- Contact payers to verify coverage
Download the APONVIE Reimbursement Guide for more details.
HOPD: hospital outpatient department.
ASC: ambulatory surgical center.
ASP: average sales price.
To learn more about APONVIE from a peer, connect with Heron to set up a clinical consult.
Connect With HeronResources
Distribution Reference Guide
Reimbursement Guide
Heron Connect Website
Important Safety Information
Contraindications
APONVIE is contraindicated in patients with a history of hypersensitivity to aprepitant or any component of the product, and in patients taking pimozide. Increased pimozide levels may cause serious or life-threatening reactions, such as QT prolongation.
Warnings and Precautions
Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis, during or soon after administration of aprepitant have occurred. Symptoms including dyspnea, eye swelling, flushing, pruritus, and wheezing have been reported. Monitor patients during and after administration.
Clinically Significant CYP3A4 Drug Interactions: Aprepitant is a substrate, weak-to-moderate (dose-dependent) inhibitor, and an inducer of CYP3A4. Use of pimozide, a CYP3A4 substrate, with APONVIE is contraindicated.
Decrease in INR with Concomitant Warfarin: Use of aprepitant with warfarin, a CYP2C9 substrate, may result in a clinically
significant decrease in the International Normalized Ratio (INR) of prothrombin time.
Monitor the INR in the 2-week period particularly at 7 to
Risk of Reduced Efficacy of Hormonal Contraceptives: The efficacy of hormonal contraceptives may be reduced for
Use in Specific Populations
Avoid use of APONVIE in pregnant women as alcohol is an inactive ingredient. There is no safe level of alcohol exposure in pregnancy.
Adverse Reactions
Most common adverse reactions (incidence ≥3%) are constipation, fatigue, and headache.
Report side effects to Heron at
Indication
APONVIE is a substance P/neurokinin-1 (NK1) receptor antagonist, indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.
Limitations of Use: APONVIE has not been studied for treatment of established nausea and vomiting.
Please see full Prescribing Information.
Connect With Heron
How could you incorporate APONVIE as the foundation of your institution's PONV management strategy? Connect with us to find out.
Fields marked with an asterisk (*) are required.
Thank You
To report an adverse event or product complaint:
844-HERON11 (844-437-6611)
heronmc@eversana.com
For general information:
Investors and Media:
For all other inquiries, please visit the Heron Therapeutics corporate website.
Go to Heron Website